The mRNA vaccines were developed using novel technology that was approved for the first time for public use during the COVID-19 pandemic.

U.S. Food and Drug Administration advisers unanimously recommended on Thursday that COVID-19 vaccines for the 2025-26 period should target newer strains of the JN.1 variant. COVID vaccine makers are ...